Curriculum Vitae

CURRICULUM VITAE

9/17/2019

Johannes W. Vieweg, M.D., FACS Founding Dean and Chief Academic Officer Professor of Surgery Kiran C. Patel College of Allopathic Medicine Nova Southeastern University Fort Lauderdale, Florida

EMPLOYMENT HISTORY Present: Founding Dean and Chief Academic Officer, Professor of Surgery, Nova Southeastern University, Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, FL 2016- Present

Past: Senior Scientific Advisor, Bureau of East Asian and Pacific Affairs, U.S. Department of State, Washington, DC 2015-2016 Founding Professor and Chairman, Department of Urology, University of Florida, Gainesville, FL 2006-2015 Vice President, Executive Committee, Florida Clinical Practice Association Inc. (Faculty Group Practice Plan), Gainesville, FL 2008-2015 Marti and Wayne Huizenga Endowed Research Scholar’s Chair, Professor of Urology, Department of Urology, College of Medicine, University of Florida, Gainesville, FL 2006-2016 Vice Chair of Research, Department of Surgery, Division of Urology, Duke University Medical Center, Durham, NC 2004-2006

EDUCATION Baccalaureate Degree: University of Regensburg, School of Medicine, Pre-Med, Regensburg, Germany 1982-1984 Advanced Degrees: Technical University of Munich, School of Medicine, MD, Munich, Germany 1984- 1988 Doctorate Thesis: Specific inhibition of myocardial phosphodiesterase-III in patients with chronic heart failure. Technical University Munich, Munich, Germany 1989 Intern Training: Intern, Technical University of Munich, Department of Surgery, Munich, Germany 1988-1990 Resident Training: Resident, University of Ulm, Department of Urology, Ulm, Germany 1990-1991 Resident in Surgery/Urology, School of Medicine, Duke University Medical Center Durham, NC 1994-1999 Fellowships: Research Fellow, Molecular Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 1991-1993 Research Fellow, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC 1993-1994

ACADEMIC APPOINTMENTS Professor of Surgery, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 2016-Present Professor/Tenure, Marti and Wayne Huizenga Endowed Research Scholar’s Chair, Department of Urology, College of Medicine, University of Florida, Gainesville, FL 2006-2016 Associate Professor of Immunology, Department of Immunology, Duke School of Medicine, Durham, NC 2004-2006 Assistant Professor of Immunology, Department of Immunology, Duke School of Medicine, Durham, NC 2001-2004 Associate Professor of Surgery/Urology (with Tenure), Department of Surgery, Division of Urology, Duke School of Medicine, Duke University Medical Center, Durham, NC 2004-2006 Associate Professor of Surgery/Urology (without Tenure), Department of Surgery, Division of Urology, Duke School of Medicine, Duke University Medical Center, Durham, NC 2001-2004 Assistant Professor of Surgery/Urology, Department of Surgery, Division of Urology, Duke School of Medicine, Duke University Medical Center, Durham, NC 1999-2001

ADMINISTRATIVE APPOINTMENTS AND POSITIONS Chairman, State of Florida Prostate Cancer Advisory Council, Gainesville, FL 2011-2015 Research Council Chair, American Urological Association, Linthicum, MD 2010-2015 Editor-in-Chief, Current Opinions in Urology, Wolters Kluwer, London 2008-Present Vice President, Executive Committee, Florida Clinical Practice Association Inc. (Practice Plan), Gainesville, FL 2007-2015 Program Leader, Experimental Therapeutics Program, University of Florida Shands Cancer Center, Gainesville, FL 2006-2012 Executive Director, University of Florida Prostate Disease Center, University of Florida, Gainesville, FL 2009-2016 Attending Surgeon, Malcom-Randall Veterans Administration Medical Center, Gainesville, FL 2006-2015 Attending Surgeon, Veterans Administration Medical Center, Asheville, NC 1999-2006 Attending Surgeon, Veterans Administration Medical Center, Durham, NC 1999-2006 Vice Chair of Research, Department of Surgery, Division of Urology, Duke School of Medicine, Duke University Medical Center, Durham, NC 2003-2006 Co-Director, Center for Genetic and Cellular Therapies, Duke School of Medicine, Duke University Medical Center, Durham, NC 1999-2006

BOARD CERTIFICATION AND LICENSURE State of Florida Licensure #ME 97192, 2006-Present State of North Carolina Licensure #97-01184, 1997-2006 (inactive) American Board of Urology Recertification #12708, 2010 Diplomat, American Board of Urology #12708, 1999 Education Commission for Foreign Medical Graduates #4936134, 1993 German Board of Medicine, 1988

U.S. GOVERNMENT SECURITY CLEARANCE U.S. Department of State, Washington DC “Secret” 2015-2020

HONORS AND AWARDS Dr. Larry Zaroff Man of Good Conscience Award, American Medical Women’s Association (AMWA), New York City 2019 Miami Health Care Heroes Award, Finalist, Greater Miami Chamber of Commerce, 2019 Power Leaders in Health Care, South Florida Business Journal, Miami, FL 2018 Nova Southeastern University (NSU) Inaugural Medical Student Class White Coat Ceremony Speaker, Fort Lauderdale, FL 2018 NSU Inaugural Medical Student Class Oath Ceremony Speaker, Fort Lauderdale, FL 2018 Inducted Member, Phi Kappa Phi Honor Society, Fort Lauderdale, FL 2017 Power Leaders in Health Care, South Florida Business Journal, Miami, FL 2017 National Academy of Sciences: Jefferson Science Fellows Distinguished Lecture, Washington, DC 2016 National Academy of Sciences, Jefferson Sciences Fellowship Award, Washington, DC 2015- 2016 Inducted Member, Clinical Society of Genitourinary Surgeons, Indianapolis, IN 2014 Inducted Member, American Association of Genitourinary Surgeons, Maywood, IL 2012 Liaison, American Urologic Association, Patient Advocacy Summit, Capitol Hill, Washington DC 2010 Representative, NIDDK Congressional Breakfast, Capitol Hill, Washington, DC 2010 University of Florida President’s Endowed Scholar Chair Award: The Wayne and Marti Huizenga Eminent Scholar Chair, Gainesville, FL 2008 21st Century World Scholars Award, State University System of Florida Board of Governors, Tallahassee, FL 2006 Inducted Member, Fellow of the American College of Surgeons. Chicago, Il 2003 Marquis Who’s Who in Medicine and Healthcare, 2002-2003 Distinguished Investigator Award, Society for Urologic Research, Linthicum, MD 2000 American Foundation of Urologic Disease, Research Scholar Award, Linthicum, MD 1998 Pfizer Scholar in Urology Award, Gainesville, FL 1998 German Research Fund Research Stipend, Bonn, Germany 1992 First Prize, Clinical Research Award of the University of Ulm, Germany 1991

UNIVERSITY AND OTHER APPOINTMENTS Nova Southeastern University (2016-Present) Member, NSU Alan Levan Ambassadors Board (NSU Community Board, Leadership & Entrepreneurship), 2017-Present Member, Shark Circle (Development and Donor Relations), 2017-Present Accreditation Oversight Liaison Committee on Medical Education (LCME), Preliminary Accreditation, ‘New Medical School’, 2017 Accreditation Oversight, Commission on Colleges of the Southern Association of Colleges and Schools, Substantive Change Prospectus ‘New Medical School’, 2017

Member, NSU President’s Council (Enterprise Strategic Advisory Board), 2016-Present Member, Dean’s Council (Academic Advisory Board to the Provost), 2016-Present Chair, Dr. Kiran C. Patel College of Allopathic Medicine Strategic Planning Committee, 2016- Present Member, Dr. Kiran C. Patel College of Allopathic Medicine, Community Advisory Board, 2016- Present Member (Non-voting), Dr. Kiran C. Patel College of Allopathic Medicine, Curriculum Committee, 2016-Present

University of Florida (2006-2016) Member, LCME Governance & Administration Subcommittee, 2013-2014 Member, College of Medicine Dean Search Committee, 2009 (Selected: Michael L. Good, MD) Vice President, Executive Committee, Florida Clinical Practice Association Inc. (Practice Plan), 2008-2015 Chair, Department of Medicine, Division of Nephrology Chief Search Committee, 2008 (Selected: Mark S. Segal MD) Member, College of Medicine Executive Finance Advisory Committee (EFAC), 2008-2015 Member, Senior Vice President of Health Affairs Search Committee, 2008 (Selected: David S. Guzick, MD) Member, College of Medicine Faculty Group Practice Recruitment Committee, 2007-2016 Member, Research and Development Committee of the North FL / South GA Veteran’s Administration Medical System, 2007-2009 Member, UF College of Medicine Dean Search Committee, 2007 (Selected: Bruce Kone, MD) Member, Clinical and Translational Science Awards (CTSA) Program Steering Committee, 2006 - 2010 Member, UF & Shands Cancer Center, 2006- 2015

Duke University (1998-2006) Member, Duke University Graduate Faculty Advisory Board, 2005-2006 Vice Chair of Research, Department of Surgery/Urology, 2004-2006 Member, Duke University Medical Center, Regulatory Compliance System Task Force, 2000- 2006 Member, Duke University Medical Center, Task Force on Cellular Treatments & Transplantation, 2000-2006 Member, Duke Comprehensive Cancer Center, 1998-2006

Other Institutions and Professional Organizations Florida Council of Deans, GME Subcommittee, Tallahassee, FL, 2018-Present Florida Council of Deans, Tallahassee, FL, 2017-Present AAMC Council of Deans, Washington, DC, 2017-Present Florida Urological Society Executive Committee, Orlando, FL, 2013-2016 American Urological Association International Academy, Linthicum, MD, 2012- 2016

Chair, State of Florida Prostate Advisory Council, (Florida Statute 381.911), Tallahassee, FL, 2011-2016 Society of Urologic Oncology Fellowship Program Director, Washington, DC, 2011- 2015 Member, Society of Urologic Oncology Program Committee, Bethesda, MD, 2010-2016 Advisory Board Member, Massachusetts General Hospital Vaccine and Immunotherapy Center, Boston, MA, 2010-2016 NIH Liaison for the American Urologic Association, Linthicum, MD, 2010-2015 Research Council Chair, American Urologic Association, Linthicum, MD, 2010-2015 Member, Southeastern Section of the American Urological Association, Committee on Education and Science, Linthicum, MD, 2009-2016 Member, ASCO Program Committee on the Developmental Therapeutics and Immunotherapy, 2003-2005

SOCIETY MEMBERSHIPS Present: Association of American Medical Colleges (AAMC) AAMC Council of Deans Florida Council of Medical School Deans Florida Medical Association Broward County Medical Association Phi Kappa Phi Honor Society Clinical Society of Genitourinary Surgeons (limited to 25 active members) American Association of Genitourinary Surgeons (limited to 75 active members) American Urologic Association American College of Surgeons

Past: American Association for the Advancement of Science American Association for Cancer Research American Society for Clinical Oncology American Association for Endourology Alachua County Medical Association Florida Urological Society Society for Basic Urologic Research Society for Urologic Oncology Society for Urology Chairpersons and Program Directors Société Internationale d’Urologie Urology Research Society German Society of Urology

EDITORIAL BOARDS Editor in Chief: Current Opinion in Urology, Wolters Kluwer, London 2008- Present Prostate Cancer and Prostatic Diseases, 2006-2012 Urologic Oncology, 2000-2016

JOURNAL REVIEWS Ad hoc Reviewer: Blood, British Journal of Urology, Cancer Research, Clinical Cancer Research, European J. Immunology, European Urology, International Journal of Cancer, Journal of Clinical Investigation, Journal of Gene, Medicine, Journal of Immunological Methods, Journal of Urology, Lancet, Nature Biotechnology, NeuroOncology, Proceeding of the National Academy of Sciences, Urologic Oncology, Urology, and others

LEGISLATIVE/ADVOCACY “Doctor of the Day”, Office of Legislative Services, Tallahassee, FL 2020 Member, Florida Council of Medical School Deans; Annual visit with Florida legislature on GME expansion, medical student/resident well-being, and the rising rate of opioid misuse, Tallahassee, FL 2017-Present Member, Broward Days HHS Impact Team. Independent, nonprofit and nonpartisan group of people advocating for the diverse needs and concerns of the citizens of Broward County, Florida. 2018 – Present. State of Florida Prostate Cancer Awareness Program - Annual Visits to Florida State Surgeon General providing prostate cancer screening and health education recommendations. Tallahassee, FL 2011-2015 Provision of Annual Reports and Legislative Agendas to the Florida Governor and State Surgeon General on prostate cancer screening and men’s health. Tallahassee, FL 2011-2015 Testimonies and Hearings at the State of Florida Senate and House of Representatives (total of 12 hearings) to establish the Florida Prostate Cancer Awareness Program (Statute 381.911) Tallahassee, FL 2011-2012 Annual American Urologic Association Congressional Outreach and Capitol Hill Visits, Washington, DC 2006-2010

INTERNATIONAL/GLOBAL AFFAIRS Lead, Cooperation Agreement with the Karolinska Institutet, Stockholm, Sweden 2018 Organizer, 1st Joint Committee Meeting (U.S. Department of State/ROC (Taiwan) delegation) on Global Cooperation and Training Framework, Academy of Sciences, Washington, DC 2017 Diplomat/US Representative, Taiwan Global Health Forum, Tainan, ROC (Taiwan) 2017 Diplomatic Lead/U.S. Representative for the U.S./ROC (Taiwan) Global Cooperation and Training Framework, Washington, DC 2016-2017 Medical Consultant, Centers for Disease Control, ROC (Taiwan), Dengue Epidemic Assessment 2016 Diplomat/U.S. Representative, Taiwan Digital Economic Forum, Taipei, ROC Taiwan 2016 Diplomat/U.S. Representative, Academia Sinica, Taipei, ROC (Taiwan) 2016 Consulting Scientist (by invitation) Qatar Foundation, Doha Qatar 2009

VISITING PROFESSORSHIPS, SITE VISITS, AND EPONYMOUS LECTURES (2015-Present) Visiting Professor, George Mason University President’s Council, Fairfax, VA 2019 LCME Site Visit at Kaiser Permanente School of Medicine, Pasadena, CA 2018 Florida International University – Distinguished Wertheim Lecture: Changing Landscape of American Health Care, Miami, FL 2016

National Academy of Sciences: Jefferson Science Fellows Distinguished Lecture, Washington, DC 2016 National Cheng Kung University: Mosquito Borne Illnesses, Tainan/Taiwan 2016 Kaohsiung Medical University (ROC/Taiwan), Distinguished Visiting Professor Lecture: Value- Based Healthcare, Kaohsiung 2015 National Taiwan University, College of Public Health: From Volume to Value, Taipei 2015 Massachusetts General Hospital: New Developments in Cancer Immunology, Boston, MA 2015 Long Island Jewish Medical Center/Cold Spring Harbor Cancer Center: Targeted Cancer Immunotherapy, Queens, NY 2015 “Global Training and Education Platforms - Implications for the U.S.-Taiwan Relationship”. United State Department of State, Washington DC September 2nd, 2015

CORPORATE AND SCIENTIFIC ADVISORY POSITION Scientific Advisory Board, Morphogenesis Inc., Tampa, FL 2018-Present Consultant (w/o compensation), Dendreon Corporation, Seattle, WA 2010-2015 Consultant (w/o compensation), Amgen Scientific Advisory Panel, 2010-2012 Chairman, Scientific Advisory Board, CureVac, Inc., Germany 2007-2010 Scientific Advisory Board, MERIX Biosciences, Durham, NC 1999-2005 Consultant, TAP Pharmaceuticals, 1999-2004 Consultant, GERON Corporation, San Jose, CA 2004-2006 Scientific Advisor, Prostate Cancer Expert Panel, NOVARTIS, East Hanover, NJ 2000-2004 Scientific Advisor for Xcyte Therapeutics, Seattle, WA 2000-2003 Scientific Advisor for AMGEN Inc., Thousand Oaks, CA 1998-2003 Scientific Advisor for GlaxoSmithKline, Brussels, Belgium 2001-2003

RESEARCH FACULTY AND FELLOWS - ACTIVE MENTORSHIP Paul Dominguez Gutierrez, PhD 2010-2016, (T32 Trainee) University of Florida, Gainesville, FL Benjamin Canales, MD, 2010-2016, (NIH KO8 Trainee), University of Florida, Gainesville, FL Adrian Clubb, MD, 2010-2011 (Research Fellow), University of Brisbane, Australia Scott Gilbert, MD, 2007-2010 (KO8 Trainee) Assistant Professor, University of Florida, Gainesville, FL Larry Yeung, MD, 2006-2009 (Research Fellow), University of Florida, Gainesville, FL Evgeniy Eruslanov, PhD, 2006-2010, Post-Doctoral Fellow, Harvard University, Boston, MA Zhen Su, MD, 2006-2008, Research Fellow, Duke University, Durham, NC Hubert Kübler, MD, 2005-2006, Research Fellow University of Ulm Germany Timothy Y. Tseng, MD, 2005-2006, Research Fellow, Duke University, Durham, NC Debashish Misra, MD, 2004-2006, Research Fellow, University College of Medical Sciences, New Delhi, India Negocdiep Le, MD, PhD, 2004-2006, Research Fellow, Stanford University, Stanford, CA Martin Fassnacht, MD, 2004-2005, Post-Doctoral Research, University of Würzburg Germany Quinton Cancel, MD, 2004-2005, Research Fellow, Duke University Medical Center, Durham, NC

Benjamin Yang, MD, 2003-2004, Research Fellow, Stanford University, Stanford, CA Shaoxi Liao, MD, PhD, 2002-2003, Post-Doctoral Research, West China University, P.R. China Christian deBeck, MD, 2002-2003, Research Fellow, Washington Hospital Center, Washington, DC Zhen Su, M.D, 2001-2010, Post-Doctoral Research, Capital University of Medical Science, Beijing, P.R. China Alon Weizer, MD, 2001-2002, Research Fellow, Baylor College of Medicine, Houston, TX Costas Lallas, MD, 2000-2001, Research Fellow, Jefferson Medical College, Philadelphia, PA Liming Wang, MD, 2000-2001 Post-Doctoral Research, Beijing Medical University, Beijing, P.R. China Michio Naoe, MD, 1999-2001, Research Fellow, Shaowa University, Tokyo, Japan Ning Wu, MD, 1999-2000, Research Fellow, Duke Medical School, Durham, NC Axel Heiser, PhD, 1998-2001, Post-Doctoral Research, Institute of Immunology, Kiel, Germany Philipp Dahm, MD. 1998-1999, Research Fellow, University of Heidelberg, Heidelberg, Germany

RESEARCH SERVICE AND REVIEW PANELS National Cancer Institute, R35 Outstanding Investigator Award Review, Rockville, MD, 2019 National Institute of Biomedical Imaging and Bioengineering, T32 Grant Review, Bethesda, MD 2016 National Cancer Institute SPORE Grant Review [Prostate], Bethesda, MD 2013 National Cancer Institute SPORE Grant Review [Thyroid, Breast, Prostate], Bethesda, MD 2012 National Cancer Institute SPORE Grant Review [Lymphoma, Prostate, Breast, Skin], Bethesda, MD 2012 National Cancer Institute P01 Program Grant Review, Rockville, MD 2011 National Cancer Institute SPORE Grant Review [Lymphoma, Prostate, Breast, Skin], Bethesda, MD 2011 National Cancer Institute ARRA Grand Opportunities Cancer Vaccines Panel, Bethesda, MD 2009 National Cancer Institute Translational Science Panel, Vienna, VA 2009 National Institutes of Health, NCI Special Emphasis Panel, Study Chair, Rockville, MD 2008 National Cancer Institute SPORE Grant Review [Bladder, Skin, Prostate], Bethesda, MD 2008 National Cancer Institute SPORE Grant Review [Lymphoma, Prostate, Breast, Skin], Bethesda, MD 2007 National Cancer Institute Clinical Oncology Study Section, Bethesda, MD 2007 National Cancer Institute SPORE Grant Review [Bladder, Skin, Prostate], Bethesda, MD 2007 Member, National Comprehensive Cancer Network (NCCN) Panel, Bethesda, MD 2001-2003 National Institutes of Health, NIAID IPCP-Novel HIV Immune Therapy Review Panel, Bethesda, MD 2005 Department of Defense, Prostate Cancer Research Program Integration Panel, Bethesda, MD 2005 National Institutes of Health, NCI Special Emphasis Panel, Bethesda, MD 2/2004 National Institutes of Health, NCI Special Emphasis Panel, Bethesda, MD 7/2004

Department of Defense, Programmatic Review Panel, Bethesda, MD 2001 Department of Defense, Programmatic Review Panel, Bethesda, MD 1999

CONFERENCES ORGANIZED Dr. Kiran C. Patel College of Allopathic Medicine Health Summit: Transitioning to Value-Based Healthcare. Fort Lauderdale, FL 2018 34th Congress of the Société Internationale D’Urologie Session “Shifting Sands: Organ-Sparing Surgery”. Glasgow, Scotland UK 2014 University of Florida Urology Seminar Series Continuing Medical Education Conference “Renal Cell Carcinoma, Stones, and Women’s Health”. Orlando, FL 2014 University of Florida Department of Urology, Visiting Professorship, (David Diamond MD) Gainesville, FL 2014 University of Florida Department of Urology, Visiting Professorship, (Peter Scardino MD) Gainesville, FL 2013 University of Florida Urology Seminar Series Continuing Medical Education Conference “High Impact Urology for the Practicing Physician”. Orlando, FL 2013 University of Florida Urology Seminar Series Continuing Medical Education Conference “Current Controversies in Urology”. Orlando, FL 2012 University of Florida Urology Seminar Series Continuing Medical Education Conference “Reconstructive Urology”. Ponte Vedra Beach, FL 2011 Cancer Immunotherapy Consortium 2011 Scientific Meeting. National Harbor, MD 2011 University of Florida Urology Seminar Series Continuing Medical Education Conference “Comparative Effectiveness & Current Best Practices in Urology”. Ponte Vedra Beach, FL 2010 University of Florida Urology Seminar Series Continuing Medical Education Conference “Quality of Care Initiatives in Urology”. St. Petersburg Beach, FL 2009 University of Florida Urology Seminar Series Continuing Medical Education Conference “Emerging Concepts in Urologic Surgery”. Gainesville FL 2008 3rd International Expert Meeting on Clinical Dendritic Cell Immunotherapy, Pinehurst, NC 2001

DEVELOPMENT NOVA SOUTHEASTERN UNIVERSITY 2018 Student Scholarships Dr. Kiran C. Patel College of Allopathic Medicine Endowed Student Scholarship Fund $20,000,000 Dr. Kiran C. Patel College of Allopathic Medicine Academic Support $5,000,000 Dooley Scholarship Fund $50,000 Messa Scholarship Fund $120,000

2019-Present Student Scholarships Triangle Community Foundation, Dean’s Scholarship Fund $200,000 Kundlas Scholarship Fund $100,000

Tran Scholarship Fund $100,000 Harlow Charitable Trust $80,000 Lachman Scholarship Fund $25,000 Short Scholarship Fund $25,000

Research Support Triangle Community Foundation $1,000,000 Harrison Research Support $50,000 Other Gifts from various sources: $1,000,000

UNIVERSITY OF FLORIDA (2006-2010) Endowed Chairs Wayne and Marti Huizenga Chair of Urology, University of Florida $2,500,000 David Cofrin MD Endowed Chair in Urologic Oncology, University of Florida $1,500,000 David Cofrin MD Endowed Chair in Medical Simulation, University of Florida $1,500,000 Mary-Ann Cofrin Endowed Chair in Urology Research, University of Florida $1,000,000

Research Support Cofrin Foundation to Support Surgical Simulation Training $200,000 Marti Huizenga Support for Urologic Research $1,000,000 Jorge Galante Foundation for Immunotherapy Research $1,500,000

RESEARCH FUNDING (PI ONLY) 2014-2016 Project: Genetically Engineered T-Cells Source: Galante Foundation Title: Chimeric Antigen Receptor with Specificity against NKT2D Funding (Total cost): $250,000

2011-2016 Project: T32 Source: NIH/NIDDK Title: T32DK094789-01A1: Training Program in Urologic Research Funding (Total Cost): $514,231

2009-2011 Source: National Institutes of Health/National Cancer Institute (ARRA) Title: 3K24CA118454-04SI: Elimination of Immature Myeloid Cells Funding: $53,765

2008-2011 Source: CureVac GmbH (Sponsored Research Agreement) Title: RnActive Encoding Prostate Cancer Antigens Funding: $4,661,774.00

2008-2010 Source: Florida Dept. of Health (BankheadColey) Title: Developing a Translational Prostate Cancer Research Program in Florida Funding (Direct/Indirect cost): $1,969,030

2008 Source: American Urological Association Education and Research, Inc. Title: Pfizer Visiting Professorship in Urology Funding: $7,500

2006-2009 Project Number:1K24CA118454-01A1 Source: NIH/NCI Title: Elimination of Immature Myeloid Cells Funding: $598,855

2005-2006 Project Number: 5RO1CA093910-04 Source: NIH/NCI Title: Telomerase RNA Transfected Dendritic Cell Vaccines Funding (Direct/Indirect cost): $284.296

2004-2010 Source: Department of Defense Title: Enhancement of Anti-Telomerase Immunity Against Prostate Cancer Funding (Direct/Indirect cost): $114,231

2004 -2006 Source: Geron Corporation (Sponsored Research Agreement) Title: Clinical Trials in Telomerase Targeted Immunotherapy Funding (Direct/Indirect cost): $3,375,000

2004-2005 Project Number: 5RO1CA089102-04 Source: NIH/NCI Title: Immunotherapy with Renal Tumor RNA Transfected Cells Funding (Direct/Indirect cost): $273,174

2004-2005 Project Number:5R21CA098446-02 Source: NIH/NCI Title: Elimination of Regulatory T Cells Funding (Direct/Indirect cost): $279,200

2002-2010 Source: VA Merit Review Award Title: Tumor RNA Transfected Dendritic Cell Vaccines Funding (Direct/Indirect cost): $470,143

2002-2006 Project Number:1RO1CA93910-01

Source: NIH Title: Telomerase RNA Transfected Dendritic Cell Vaccines Funding (Direct/Indirect cost): $1,546,337

2001-2005 Source: VA Merit Award Title: Tumor RNA Transfected Dendritic Cell Vaccines Funding (Direct/Indirect cost): $556,051

CLINICAL TRIALS AND RESEARCH STUDIES Study Title: A Randomized. Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-center Study to Assess Efficacy and Safety of Solifenacin Succinate to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy Protocol 905-UC-050 Status: Closed Principal Investigator: Johannes Vieweg, MD

Study Title: Phase 3, Randomized, Double blind, Placebo-controlled Study of Abiraterone Acetate (CB 7630) plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer Western IRB Number: 20090335 Status: Closed Principal Investigator: Johannes Vieweg, MD

Study Title: Phase I/II Study of Active immunotherapy using RNActive Encoding Prostate Cancer Antigens in Patients with Hormone Refractory Prostate Cancer Western IRB Number: 20082108 Status: Closed Principal Investigator: Johannes Vieweg, MD

Study Title: Phase I/II Study of Active Immunotherapy with Mature, Human Telomerase Reverse Transcriptase Messenger RNA -Transfected, Autologous Dendritic Cells (DC) Administered In a Prime-Boost Format to Subjects with Metastatic Prostate Cancer Short Title: hTERT mRNA Transfected Dendritic Cell Vaccines UF – IRB Number: 134-2007 Status: Closed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: A Pilot Study of Active Immunotherapy Using Telomerase RNA-Transfected Dendritic Cells Following Depletion of Immature Myeloid Cells Using the Differentiation Agent Tretinoin (Vesanoid®) in Subjects with Advanced or Metastatic Renal Cell Carcinoma UF – IRB Number: Pending DUHS - IRB Number: 6869-05-0R0 Status: Closed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Functional Analysis of Human Dendritic Cells DUHS - IRB Number: 1223-04-6R6 Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: In-Vitro Generation of Tumor Specific Cytotoxic T-Lymphocytes Using DC Pulsed with Autologous Tumor RNA DUHS - IRB Number: 1479-04-9R6 Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Markers of Tumor Neo-vasculature Expressed in Human Cancer DUHS - IRB Number: Pending Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Phase I Trial of Active Immunotherapy of Metastatic, Hormone Refractory Prostate Cancer Using DC Pulsed with PSA messenger RNA DUHS - IRB Number: 000408-01-3R2 Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: A Pilot Study Evaluating the Migratory Patterns of Immature and In vitro Matured Dendritic Cells Transfected with RNA Encoding PSA in Patients with Metastatic Prostate Cancer DUHS - IRB Number: 3185-03-10R2 Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: A Phase I Trial of Active Immunotherapy of Metastatic Renal Cell Carcinoma Using Autologous DC Transfected with Autologous Total Tumor RNA DUHS - IRB Number: 1716-03-5R4ER Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Phase I Study using Autologous Dendritic Cells Transfected with Amplified Tumor RNA DUHS - IRB Number: 0759-02-3R3 Status: Closed DVAMC - IRB Number: 001 Status: Open for Analysis IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Active Immunotherapy with Mature, Tumor RNA-Transfected, Autologous Dendritic Cells with or without IL-2-Diptheria Toxin Conjugate Denileukin Difitox (ONTAK®)) in Patients with Metastatic Renal Cell Carcinoma DUHS - IRB Number: 3453-04-2R2 Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: A Pilot Study of Mature, Total-Tumor RNA-Transfected, Donor-Derived Dendritic Cell Therapy in Patients Who Have Undergone Nonmyeloblative Allergenic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma, Metastatic Melanoma, or Hematologic Malignancy DUHS - IRB Number: 4900-04-7R1 Status: Completed

IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Active Immunotherapy with Mature, Tumor RNA-Transfected Autologous Dendritic Cells w/or w/out Interferon-α in Patients with Metastatic Melanoma DUHS - IRB Number: 3839-03-6R1ER Status: Closed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Phase I Study of Active Immunotherapy of Metastatic Prostate Carcinoma Using Autologous Mature Dendritic Cells (DC) Transfected w/ RNA Encoding Human Telomerase Reverse Transcriptase (hTERT) DUHS - IRB Number: 3034-04-9R3 Status: Completed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Active Immunotherapy with Mature, Human Telomerase Reverse Transcriptase RNA- transfected, Autologous Dendritic Cells w/or w/out the IL-2 Diphtheria Toxin Conjugate Denileukin Difitox (ONTAK®)) in Subjects with Metastatic Prostate Cancer DUHS - IRB Number: 5278-03-10R0 Status: Completed DVAMC - IRB Number: 0857 Status: Completed IND Sponsor: Johannes Vieweg, MD

Study Title: A Pilot Study Evaluating the Migratory Patterns of 111-Indium-Labeled Immature Dendritic Cells Injected Intradermally Following In-situ Priming with the Immune Stimulator Imiquimod (Aldara®)) DUHS -IRB Number: 4361-03-12R1ER Status: Closed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: Phase II Study of Active Immunotherapy Using Matured PSA mRNA-Loaded Dendritic Cells Co-transfected with OX40 Ligand mRNA in Patients with Metastatic Prostate Cancer DUHS - IRB Number: 4718-03-4R0 Status: Closed IND Sponsor/Principal Investigator: Johannes Vieweg, MD

Study Title: A Phase I Study of Active Immunotherapy with LAMP hTERT RNA Transfected DC in Patients with Metastatic Prostate Cancer Using Escalating Doses of In-Situ Priming with the Immunostimulant Imiquimod (Aldara®)) DUHS - IRB Number: 5854-04-5R0 Status: Completed DVAMC - IRB Number: 00901 Status: Completed IND Sponsor: Johannes Vieweg, MD

Study Title: Active Immunotherapy with Mature, Human Telomerase Reverse Transcriptase RNA- Transfected, Autologous Dendritic Cells with or without the IL-2 Diphtheria Toxin Conjugate Denileukin Difitox (ONTAK®) in Subjects with Hematologic Malignancies DUHS - IRB Number: 4900-04-7R1

Status: Closed IND Sponsor: Johannes Vieweg, MD

INVESTIGATIONAL NEW DRUG APPLICATIONS (FDA) BB-IND 11705, Immature, LAMP hTERT mRNA Transfected Autologous Dendritic Cells, 2004- 2010 BB-IND 10036, Dendritic Cells Transfected with mRNA encoding hTERT; Dendritic Cells Transfected with influenza m1 messenger RNA (2001-present). Acquired by Geron Corporation, Menlo Park, CA BB-IND 8769, Autologous Dendritic Cells Transfected with Autologous Total Tumor RNA, 1999- 2006 BB-IND 8319, Autologous Dendritic Cells Pulsed with PSA messenger RNA, 1999-2004

SUBMITTED PATENTS (University of Florida) Pluripotent Stem Cell Transcription Factor Network in Prostate Tumor-Initiating Cells Methods and Compositions for Enhancement of Antitumor Immunity by In Vivo Depletion of Immunosuppressive Cell Activity

PEER-REVIEWED ARTICLES ORIGINAL, PEER REVIEWED RESEARCH 1. Vieweg J, Sainfort F, Jacko JA, Wales Paula S. Management Principles to Drive the Creation of a 21st Century Medical School. Acad Medicine. 2019. Under Review.

2. Vieweg J, Leinen P, Verwey WB, Shea CH, Panzer S. The Cognitive Status of Older Adults: Do Reduced Time Constraints Enhance Sequence Learning? J Mot Behav. 2019 Aug 25:1-12.

3. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother. Cancer. 2016 Dec 20; 4:92.

4. Bae K.M., Dai Y, Vieweg J, Siemann D.W. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. Am J Cancer Res. 2016 May 1;6(5):1078-88.

5. Kusmartsev S, Dominguez-Gutierrez PR, Canales BK, Bird VG, Vieweg J, Khan SR. Calcium Oxalate Stone Fragment and Crystal Phagocytosis by Human Macrophages. J Urol. 2016 Apr;195(4 Pt 1):1143-51.

6. Butler GJ, Kenyon DJ, Gorenstein S, Davenport T, Golembe E, Lee B, Vieweg J. Oxy-Mat™ Mattress System Development Utilizing Simultaneous Measurement of Interface Pressure and Deep Tissue Oxygen Saturation. Surg Technol Int. 2015 May; 26:71-82. 7. Gupta, M., McCauley, J, Farkas, A, Gudeloglu, A, Neuberger, MM, Vieweg, J, Dahm, P. Clinical Practice Guidelines on Prostate Cancer, A Critical Appraisal. J Urol. 2015 Apr;193(4):1153-8. doi: 10.1016/j.juro.2014.10.105.

8. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; Vieweg, J, and COU

investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy- naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. 9. Sefah, K., Bae K.M., Phillips J.A., Siemann D.W., Su Z., McClellan S., Vieweg J., Tan W. Cell-Based Selection provides novel molecular probes for cancer stem cells. Intl J Cancer. 2013: 132(11):2578-88. 10. Parekattil, S.J., Gudeloglu, A., Brahmbhatt, J.V., Prioloa, K.B., Vieweg, J., Allan, R.W. Trifecta nerve complex: potential anatomical basis for microsurgical denervation of the spermatic cord for chronic orchialgia. J Urol. 2013. 1901: 265-70. 11. Eruslanov, E., Stoffs, T., Kim, W.J., Daurkin, I., Gilbert, S.M., Su, L.M., Vieweg, J., Daaka, Y., Kusmartsev, S. Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res. 2013. 19(7):1670-80. 12. Eruslanov E., Neuberger, M., Daurkin, I., Perrin, G.Q., Algood, C., Dahm, P., Rosser, C., Vieweg, J., Gilbert, S.M., Kusmartsev, S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2012 March; 130(5):1109-19. 13. Santos, N., Wenger, J.B., Havre, P., Liu, Y., Dagan, R., Imanirad, I., Ivey, A.M., Zlotecki, R.A., Algood, C.B., Gilbert, S.M., Allegra, C.J., Okunieff, P., Vieweg, J., Dang, N.H., Luesch, H., Dang, L.H. Combination therapy for renal cell cancer: what are possible options? Oncology. 2011;81(3- 4):220-9. 14. Bae, K.M., Parker, N.N., Dai, Y., Vieweg, J., Siemann, D.W. E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res. 2011;1(1):71-84. Epub2010 Oct 20. 15. Daurkin, I., Eruslanov, E., Stoffs, T., Perrin, G.Q., Algood, C., Gilbert, S.M., Rosser, C.J., Su, L.M., Vieweg, J., Kusmartsev, S. Tumor-associated macrophages mediate immune suppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Research. 2011 September 7. 16. Eruslanov E., Neuberger, M., Daurkin, I., Perrin, G.Q., Algood, C., Dahm, P., Rosser, C., Vieweg, J., Gilbert, S.M., Kusmartsev, S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2011 April 7. 17. Eruslanov, E., Daurkin, I., Vieweg, J., Daaka, Y., Kusmartsev, S. Aberrant PGE (2) metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. International Immunopharmacology. 2011 July; 11(7):848-55. 18. Djulbegovich, M., Beyth, R.J., Neuberger, M., Stoffs, T., Vieweg, J., Dahm, P. Screening for prostate cancer, systematic review and meta-analysis of randomized control trials. British Medical Journal 2010 September; 14; 341. 19. Turpen, R.M., Fesperman, S.F., Smith, W.A., Vieweg, J., Dahm, P. Reporting quality and information consistency of randomized, controlled trials presented as abstracts at the American Urological Association Annual Meetings. J Urology 2010 July; 184(1): 249-53. 20. Eruslanov E., Daurkin, I., Ortiz, J., Vieweg, J., Kusmartsev, S. Tumor-mediated induction of myeloid- derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catablolism in myeloid cells. J Leukocyte Biology 2010, 88:839-48. 21. Bae, K, Su, Z, Frye, C, McClellan, S, Allan, RW, Andrejewski, JT, Kelley, V, Jorgensen, M, Steindler, DA, Vieweg, J, Siemann, DW. Expression of Pluripotent Stem Cell Reprogramming Factors by Prostate Tumor-Initiating Cells. J Urology 2010 May; 183(5):2045-53.

22. Daurkin I, Eruslanov E, Vieweg J, and Kusmartsev S. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immun Immunother. 2010 May; 59(5):697-706. 23. Gopalakrishnan, S., Van Emburgh, B., Shan, J., Su, Z., Fields, C.R., Vieweg, J., Hamazaki, T., Schwartz, P.H., Terada, N., Robertson, K.D. A Novel DNMT3B Splice Varian Expressed in Tumor and Pluripotent Cells Modulates Genomic DNA Methylation Patterns and Displays Altered DNA Binding. Molecular Cancer Research 2009; Oct 7(10): 1622-34. 24. Kusmartsev, S., Vieweg, J. Enhancing the Efficacy of Cancer Vaccines in Urologic Oncology: New Directions. Nat Rev Urol. 2009; Oct 6(10): 540-9. 25. Pop, G.H., Fesperman, S.F., Ball, D.A., Yeung, L.L., Vieweg, J., Dahm, P. Duplicate Presentations on Prostate Cancer at American Urological Association and European Association of Urology Annual Meetings. J Urol. 2009: Aug 182(2): 674-8; discussion 678-9. 26. Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, and Kusmartsev S. Altered expression of 15-PGDH in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009: 182: 7548-57. 27. Tseng, T.Y., Breau, R.H., Fesperman, S.F., Vieweg, J., Dahm, P.: Evaluating the Evidence – the Methodological and Reporting Quality of Comparative Observational Studies of Surgical Interventions in Urological Publications. BJU Int. 2008; 103(8) 1026-31. 28. Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kübler, H., Yancey, D., Dahm, P., Vieweg, J.: Reversal of Myeloid Cell-mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2008; 14(24) 8270-8. 29. Su, Z., Frye, C., Bae, K., Kelley, V., Vieweg, J.: Differentiation of Human Embryonic Stem Cells into Immunostimulatory Dendritic Cells Under Feeder-Free Culture Conditions. Clinical Cancer Research 2008; 14(19) 6207 – 6217. 30. Scales, C.D., Jr., Norris, R.D., Preminger, G.M., Vieweg, J., Peterson, B.L., Dahm, P.: Evaluating the Evidence: Statistical Methods in Randomized Controlled Trial in the Urological Literature. J. Urol. 2008; 180(4): 1463-7. 31. Yeung, L.L., Vieweg, J., Khan, S.R., Newman, R.C., Dahm, P.: A Tribute to the Life and Accomplishments of Birdwell Finlayson. J. Urol. 2008; 179(3): 842-6. 32. Kusmartsev, S., Eruslanov, E., Kübler, H., Tseng, T., Sakai, Y., Su, Z., Kaliberov, S., Heiser, A., Rosser, C., Dahm, P., Siemann, D., Vieweg, J.: Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma. J. Immunol. 2008; 181(1): 346-53. 33. Fesperman, S.F., West, C.S., Bischoff, C.J., Algood, C.B., Vieweg, J., Dahm, P.: Study Characteristics of Abstracts Presented at the Annual Meetings of the Southeastern Section of the American Urological Association (1996 – 2005). J. Urol. 2008; 179(2): 667-71. 34. Borawski, K.M., Norris, R.D., Fesperman, S.F., Vieweg, J., Preminger, G.M., Dahm, P.: Levels of Evidence in the Urological Literature. J. Urol. 2007; 178(4 Pt. 1): 1429-33. 35. Kubler, H., Tseng T.Y., Sun, L., Vieweg, J., Harris, M.J., Dahm, P.: Impact of Nerve Sparing Technique on Patient Self-Assessed Outcomes after Radical Perineal Prostatectomy. J Urol 2007; 178: 488-492. 36. Vieweg, J., Su. Z., Dahm, P. & Kusmartsev, S.: Reversal of Tumor-Mediated Immunosuppression. Clin Cancer Res 2007, Jan 15; 13: 727s-732s.

37. Tseng, T.Y., Cancel Q.V., Fesperman, S.F., Kuebler, H.R., Sun, L., Roberston, C.N., Polascik, T.J., Moul, J.W., Vieweg, J., Albala, D.M., Dahm, P.: The Role of Early Adopter Bias for New Technologies in Robot Assisted Laparoscopic Prostatectomy. J Urol 2007; 177:1318-1323. 38. Smith, W.A., Cancel, Q.V., Tseng, T.Y., Sultan, S., Vieweg, J., Dahm, P.: Factors Associated with the Full Publication of Studies Presented in Abstract Form at the Annual Meeting of the American Urological Association. J Urol 2007; 177:1084-1088. 39. Scales, C.D. Jr., Norris, R.D., Keitz, S.A., Peterson, B.L., Preminger, G.M., Vieweg, J., Dahm, P.: A Critical Assessment of the Quality of Reporting of Randomized, Controlled Trials in the Urology Literature. J Urol 2007;177: 1090-1094. 40. Yang, B.K., Gan, T.J., Salmen, C.R., Cancel, Q.V. Vieweg, J. & Dahm, P.: Radical Perineal Prostatectomy for Treatment of Localized Prostate Cancer in Obese and Nonobese patients: A Matched Control Study. Urology 2006; 67: 990-995. 41. Dannull, J., Su, Z, Rizzieri, D., Yang, B.K., Coleman, D., Yancey, D., Zhang, A., Dahm, P., Chao, N., Gilboa, E., & , Vieweg, J.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clinical Investigation 2005;115: 3623-3633. 42. Dannull, J., Su, Z., Boczkowski, D, Nair, S., Yancey, D, Gilboa, E. & Vieweg, J.: Enhanced antigen presenting function of terminally matured dendritic cells after co-transfection with OX40 Ligand mRNA. Blood 2005; 105:3206-3213. 43. Su, Z., Dannull J., Yang, B., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Nair, S., Boczkowski, D., Gilboa, E. & Vieweg, J.: Telomerase mRNA transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T-cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-3807. 44. Yang, B.K., Young, MD, Calingaert, B., Alabala, D.M., Vieweg, J., Murphy, B.C. & Dahm, P.: Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. J Urol 2004;172:264-68. 45. Gilboa, E., Vieweg, J., Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004, 199:251-63. 46. Cisco, R., Abdel-Weinab, Z., Dannull, J., Nair, S., Tyler, D., Gilboa, E., Vieweg, J., Daaka, Y. & Pruitt, S.: Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol 2004;172:7162-68. 47. Nair, S., McLaughlin, C., Weizer, A., Su, Z., Boczkowski, D., Dannull, J., Vieweg, J. & Gilboa, E.: Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-82. 48. Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J. & Gilboa, E.: Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003;102:964-971. 49. Su, Z., Dannull, J., Heiser, A., Yancey, D., Pruitt, S., Madden, J., Coleman, D., Niedzwiecki, D., Gilboa, E. & Vieweg, J.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA transfected DC. Cancer Res 2003;63:2127-2133. 50. Young, D., Weizer, A., Silverstein, A., Crisci, A., Albala, D., Vieweg, J., Paulson, D. & Dahm, P.: Urinary continence and quality of life in the first year after radical perineal prostatectomy. J Urol 2003;170:2374-78.

51. Weizer, A., Silverstein, A., Young, M., Vieweg, J., Paulson, D. & Dahm, P.: A prospective evaluation of pain medication requirements and recovery after radical perineal prostatectomy. Urology 2003;62:693-697. 52. Dahm, P., Silverstein, A., Weizer, A., Crisci, A., Vieweg, J. & Paulson, D.: When to diagnose and how to treat prostate cancer in the ‘not too fit’ elderly. Crit Rev Oncol Hematol 2003;48:123-131. 53. Dahm, P., Silverstein, A., Weizer, A., Young, M., Vieweg, J., Albala, D. & Paulson, D.F.: A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy. J Urol 2003;169:2220-24. 54. Vieweg, J., Su, Z., Weizer, A., Dahm, P., Yancey, D., Turaga, V., Higgins, J., Boczkowski, D., Gilboa, E. & Dannull, J.: Enhanced induction of telomerase-specific CD4+ T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002;62(17):5041-48. 55. Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M., Lallas, C., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-417. 56. Heiser, A., Maurice, M., Yancey, D., Coleman, D., Dahm, P. & Vieweg, J.: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001;61:3388-93. 57. Heiser, A., Maurice, M., Yancey, D., Wu, N., Dahm, P., Pruitt, S., Boczkowski, D., Nair, S., Ballo, M., Gilboa, E. & Vieweg, J.: Induction of polyclonal prostate cancer specific cytotoxic T lymphocytes using dendritic cells transfected with amplified tumor RNA. J Immunol 2001;166:2953-60. 58. Gregori, A., Vieweg, J., Dahm, P. & Paulson, D.: Comparison of ultrasound – guided biopsies and prostatectomy specimens: Predictive accuracy of Gleason score and tumor site. Urol Internatl 2001;66:66-71. 59. Nair, S.K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J., Vieweg, J. & Gilboa, E.: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6(8):1011-17. 60. Heiser, A., Dahm, P., Yancey, D., Maurice, M., Boczkowski, D., Nair, S., Gilboa, E. & Vieweg, J.: Human dendritic cells transfected with RNA encoding prostate specific antigen (PSA) stimulate prostate specific CTL responses in vitro. J Immunol 2000;164(10):5508-14. 61. Gschwend, J., Fair, W. & Vieweg, J.: Contemporary results of radical cystectomy. Eur J Urol 2000;42:136-142. 62. Dahm, P., Roland, F., Vaslef, S., Moon, R., Price, D., Georgiade, G. & Vieweg, J.: Outcome analysis in patients with primary necrotizing fascitis of the male genitalia. Urology 2000;26:32-38. 63. Dahm, P.,Vieweg, J., Newhall, P., Roberston, J. & Paulson, D.: Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy. World J Urol 2000;18(3):173-178. 64. Vieweg, J., Gschwend, J., Herr, H. & Fair, W.: The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 1999;161:72-76. 65. Vieweg, J., Gschwend, J., Herr, H. & Fair, W.: Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449-454. (Selected as CME Article). 66. Dahm, P., Vieweg, J., Gregori, A., Robertson, J. & Paulson, D.: Editorial: Trends and indications of radical perineal prostatectomy. Aktuelle Urologie 1999;5:345-346.

67. Dahm, P., Vieweg, J., Iselin, C., Gregori, A., Robertson, J. & Paulson, D.: Outcome in radical perineal prostatectomy. Aktuelle Urologie 1999;5:347-351. 68. Price, D., Vieweg, J., Roland, F., Coetzee, L., Spalding, T., Iselin, C. & Paulson, D.: Transient lower extremity neuropraxia associated with radical perineal prostatectomy: A complication of the exaggerated lithotomy position. J Urol 1998;160:1376-1378. 69. Vieweg, J., Teh, C., Freed, K., Leder, R., Nelson, R. & Preminger, G.: Unenhanced helical computerized tomography scanning for the evaluation of patients with acute flank pain. J Urol 1998;160:1-5 (Selected as CME article). 70. Preminger, G., Vieweg, J., Leder, R. & Nelson, R.: Urolithiasis: Detection and management with unenhanced spiral CT - A urologic perspective. Radiology 1998;207:308-309. 71. Freed, K., Frederick, M., Shusterman, D., Paulson, E., Keogan, M., Vieweg, J., Smith, R., Nelson, R., Delong, D., Preminger, G. & Leder, R.: Interobserver variability in the interpretation of unenhanced helical CT scan for the diagnosis of ureteral stone disease. J Computer Assisted Tomography (JCAT) 1998; 22:732-737 (Recipient of the Giovanni Di Chiro Award for Outstanding Scientific Research, 1998). 72. Iselin, C., Robertson, C., Webster, G., Vieweg, J. & Paulson D.: Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? J Urol 1997;157:201-213. 73. Vieweg, J., Boczkowski, D., Roberson, K., Edwards, D., Robertson, C. & Gilboa, E: Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995;55:2366-72. 74. Vieweg, J., Rosenthal, F., Bannerji, R., Heston, W., Fair, W., Gansbacher, B. & Gilboa, E.: Immunotherapy of prostate cancer in the Dunning rat model: The use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:1760-65. 75. Vieweg, J., Heston, W., Gilboa, E. & Fair, W.: An experimental model simulating local recurrence and pelvic metastasis following orthotopic induction of prostate cancer. Prostate 1994;24:291-298. 76. Vieweg, J., Whitmore, W., Herr, H., Sogani, P., Russo, P., Sheinfeld, J. & Fair, W.: The role of radical cystectomy and pelvic lymphadenectomy in node positive bladder cancer -The MSKCC experience. Cancer 1994;73:3020-28. 77. Coveney, E., Clary, B., DiMaio, J., Vieweg, J. Gilboa, E. & Lyerly, H.: Inhibition of breast cancer metastases by cytokine gene modified tumor vaccination in tumor bearing mice. Surg Forum 1994;45:540-542. 78. Clary, B., Vieweg, J., Philip, R., Coveney, E., DiMaio, J., Gilboa, E. & Lyerly, H.: Adeno- associated virus plasmid: cationic liposomal mediated gene transfer results in significant cytokine expression in human tumor cells following lethal irradiation. Surg Forum 1994;45:530-533. 79. Vieweg, J., Weber, H., Miller, K. & Hautmann, R.: Female fertility after extracorporeal shock wave lithotripsy. J Urol 1992;148:1007-10. 80. Von Gumppenberg, S., Vieweg, J. & Claudi, B.: Fixateur interne bei frakturen der brust- und lendenwirbelsäule. Hefte Unfallheilkunde 1992;6:217-219. 81. Baumann, G., Ningel, K., Vieweg, J., Joderohl, A. & Cremer, G.: Piroximone, dobutamine and nitroprusside. Comparative effects on hemodynamics in patients with congestive heart failure. Eur Heart J 1991;12:533-540.

82. Kleinschmidt, K., Vieweg, J., Gottfried, H., Miller, K. & Hautmann, R.: Intra-and postoperative morbidity after radical prostatectomy. Urologe A 1991;30:387-393. 83. Vieweg, J., Heidecke, K., Beckurts, T. & Hölscher, M.: Postischemic normal function after HTK perfusion in living-related kidney transplatation. Urologe A 1991;30(4):256-259. 84. Von Gumppenberg, S., Vieweg, J., Claudi, B. & Harms, J.: Primary surgical therapy of acute thoracic and lumbar spine injuries. (Die Primäre Versorgung der Frischen Verletzung von Brust- und Lendenwirbelsäule). Aktuell Traumatol 1991;21(6):265-273. 85. Von Gumppenberg, S., Allgayer, B., Vieweg, J. & Claudi, B.: Validity of magnetic resonance imaging in the diagnosis of injured intervertebral disks. Langenbeck’s Arch Chir 1991; 376:346-350.

EDITORIALS, INVITED REVIEWS, BOOK CHAPTERS, AND COMMENTARIES 1. Vieweg J.: NSU is equipping next generation of health care leaders. SunSentinel, July 2018 2. Vieweg J.: Reengineering Science and Technology Policy to Address 21st Century Challenges. Jefferson Science Fellows Distinguished Lecture Series, February 2016 3. Vieweg, J.: Personalizing Active Surveillance for Prostate Cancer. AUA News, January 2015 4. Vieweg, J.: Cancer Prevention, the Road We Must Take. AUA News, May 2014 5. Vieweg, J.: Big Data in Biomedical Research. AUA News, January 2014 6. Vieweg, J.: The Evolution of NIDDK’s George M. O’Brien Research Centers Program. AUA News, November 2013 7. Vieweg, J.: Evaluating Research Quality. AUA News, September 2013 8. Vieweg, J.: New Directions in Cancer Research. AUA News, March 2013 9. Vieweg, J.: Mission Imperative – The Mastery of Team Science. AUA News, January 2013 10. Vieweg, J.: Building Academic-Community Partnerships Through Participatory Research. AUA News, September 2012 11. Vieweg, J.: Comparative Effectiveness Research in Urology. AUA News, June 2012 12. Vieweg, J.: Editorial Comment: Is Bilateral Extended Pelvic Lymphadenectomy Necessary for Strictly Unilateral Invasive Bladder Cancer? J Urology. 2012: 187(5): 1582 13. Vieweg, J.: Commentary on Prostate Cancer Guidelines. AUA News, March 2012 14. Vieweg, J.: Vaccine Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma. In: Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic Targets. Ed: Figlin, Rathmell, Rini. 2012 Springer Publishing. Philadelphia, PA 15. Vieweg, J. Preventive Healthcare Science. AUA News, January 2012 16. Vieweg, J. The AUA Office of Research Charging Ahead. AUA News, November 2011 17. Vieweg, J. Aging Research – Time to Get Serious About It. AUA News, September 2011 18. Vieweg, J. New Trends and Opportunities in Urologic Research. AUA News, July 2011 19. Vieweg, J. NIH Budget Cuts and Implications on Urologic Research. AUA News, May 2011 20. Vieweg, J. Urologic Research – It All Starts with Education. AUA News, March 2011

21. Vieweg, J. Communicating Urologic Research. AUA News, January 2011 22. Vieweg, J. Increasing the Talent Pool in Urologic Research. AUA News, November 2010 23. Vieweg, J. Enduring Support for Urologic Research. AUA News, September 2010 24. Vieweg, J. International Medical Graduates in United States Urology Training Programs. AUA News, July 2009 25. Kusmartsev, S., Vieweg, J. New Directions to Enhance the Efficacy of Cancer Vaccines in Urological Oncology. Nature Reviews Urology 2009; 6: 540-549 26. Vieweg, J. Prostate Cancer: Targeting Complexity. Curr Opin Urol. 2008; 18(3): 261-2 27. Vieweg, J. Immunotherapy for Advanced Prostate Cancer. Rev Urol 2007; 9 Supp 1: S29-S38 28. Vieweg, J. The evolving therapeutic landscape of prostate cancer. Curr Opin Urol 2007;17:156 29. Vieweg, J., Su, Z., Dahm, P. & Kusmartsev, S.: Reversal of Tumor-Mediated Immunosuppression. Clin Cancer Res 2007, Jan 15;13:727s-732s 30. Kubler, H., Vieweg, J., Vaccines in Renal Cell Carcinoma, Semin Oncol 2006;33:614-624 (Invited review article) 31. Vieweg, J. Emerging molecular concepts for prostate cancer immunotherapy. In: Prostate Cancer: Surgical Principles and Practice, Ed: Kirby, Partin, Fenley, & Parsons, Lippincott Williams & Wilkins, 2006 32. Vieweg, J. Future directions for vaccine-based therapies. Urol Oncol 2006;24:448-455 (invited review article) 33. Gutheil, J., Keilholz, U., Loibner, H., Parmiani, G., Romero, P., Scharschmidt, B., Vieweg, J: The Use of Clinical Endpoints in Cancer Vaccine Trials to Support Efficacy. Cancer Vaccine Clinical Trials Working Group. J Soc Biol Ther, 2005: 13-26 34. Sanda, M.G., DiPaola, R.S., Drake, C.G., Simons, J., Vieweg, J.: Vaccine immunotherapies in prostate cancer, 2005 (CME Monograph) 35. Moul, J., George, D., Vieweg, J.: Commentary: Promising phase II results for lenalidomide in metastatic renal cell cancer. Oncol Report 2005;pp. 57-58 36. Moul, J., George, D., Vieweg, J.: Commentary: APC8015 vaccine on fast track against prostate cancer. Oncol Report 2005;pgs 51-60 37. Vieweg, J: Commentary: Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma? Nat Clin Prac Oncol 2005;2(4):192-193 38. Vieweg, J. & Dannull, J.: Vaccine therapy for prostate cancer. Nat Clin Prac Urol, 2005;2(1):44- (invited review article) 39. Vieweg, J. & Jackson, A.: Antigenic targets for renal cell carcinoma immunotherapy. Exp Opin Biol Ther 2004;4(11):1791-1801 (invited review article) 40. Vieweg, J. & Jackson, A.: Modulation of antitumor responses by dendritic cells. Springer Sem Immunopathol 2005;26(3):329-341. (invited review article) 41. Dahm, P., Vieweg, J. & Paulson, D.: Radical perineal prostatectomy. In: Urologic Oncology, 2005:528- 535

42. Morse, M.A., Lyerly, H.K., Clay, T.M., Abdel-Wahab, O., Chui, S.Y., Garst, J., Gollob, J., Grossi, P.M., Kalady, M., Mosca, P.J., Onaitis, M., Sampson, J.H., Seigler, H.F., Toloza, E.M., Tyler, D., Vieweg, J. & Yang, Y.: Immunotherapy of surgical malignancies. Curr Probl Surg 2004;41(1):15-132 (invited review article) 43. Gilboa, E. & Vieweg, J.: Cancer immunotherapy with mRNA transfected dendritic cells. Immunol Rev 2004;199(1):251-263 (Invited review article) 44. Vieweg, J. & Dannull, J.: Immunotherapy and vaccines in prostate cancer. In: Management of Prostate Cancer, Ed: Kenneth B. Cummings, Marcel Dekker Inc. New York, Sept. 2004. (invited review article) 45. Dahm, P. & Vieweg, J.: Emerging immunotherapeutic approaches for urologic malignancies. AUA Update Series, Volume XII, 2004. (Invited review article) 46. Vieweg, J. & Dannull, J.: Tumor vaccines: From gene therapy to dendritic cells – The emerging frontier. Urol Clin N Amer 2003;30:633-643 (Invited review article). 47. Vieweg, J.: Immunotherapy: Concepts and application. AUA, Office of Education, Educational Program Syllabus, Orlando, FL, May 2002 48. Paulson, D. & Vieweg, J.: Radical Perineal prostatectomy: a model for evaluating local response of prostate therapy. Crit Rev Oncol Hematol 2002;43(2):135-139 49. Gschwend, J., Fair, W. & Vieweg, J.: Radical cystectomy for invasive bladder cancer: Contemporary results and remaining controversies. Eur Urol 2000;38:121-130 50. Vieweg, J: The evolving role of dendritic cell therapy in urologic oncology. Curr Opin Urol 2000;10:307-312 51. Gschwend, J., Vieweg, J. & Fair, W.: Radical cystectomy for invasive bladder cancer - Contemporary results and remaining controversies. AUA Update Series 1999; Lesson 13, Volume XVIII. (invited review article) 52. Vieweg, J.: Principles of gene therapy. Der Urologe 1996; 35: 378-389. (Invited review article) 53. Vieweg, J. & Fair, W.: Pelvic lymph node dissection for carcinoma of the urinary bladder. AUA Update Series 1996; Lesson 39, Volume XV. (Invited review article) 54. Vieweg, J. & Gilboa, E.: Gene therapy approaches in urologic oncology. Surg Oncol Clin N Amer 1995;4:203-218 (Invited review article) 55. Vieweg, J. & Gilboa, E.: Considerations for the use of cytokine secreting tumor cell preparations for cancer treatment. Cancer Invest 1995;13:193-201 56. Gilboa, E., Lyerly, H., Vieweg, J. & Saito, S.: Immunotherapy of cancer using cytokine gene modified tumor vaccines. Seminars Cancer Biol 1994;5:409-417 57. Vieweg, J. & Hölscher, M.: HTK-protection in living-related kidney transplatation. In: Medizin im Blickpunkt, Edited by G. Kirste. Innovations-Verlags-Gesellschaft 1992:50-53

ABSTRACTS AND PRESENTATIONS Invited Presentation: Business Principles to Drive the Creation of a 21st Century Medical School. Vienna Medical Academy, Vienna Austria, 2019. Invited Presentation: Accreditation Requirements for Allopathic Medical Schools. George Mason University President’s Council, Fairfax, VA 2019. Invited Presentation: Organizational Framework of a 21st Century Medical School. Duke Urologic Assembly, Hilton Head, SC, 2018. Florida International University – Distinguished Wertheim Lecture: Changing Landscape of American Health Care, Miami, FL 2016. Jefferson Science Fellows Distinguished Lecture. National Academy of Sciences, Washington, DC 2016. Guest Lecturer: Mosquito Borne Illnesses, National Cheng Kung University, Tainan/Taiwan 2016. Guest Lecturer: Value-Based Healthcare. Kaohsiung Medical University (ROC/Taiwan), Kaohsiung 2015. Guest Lecturer: From Volume to Value. National Taiwan University, College of Public Health, Taipei 2015 Global Training and Education Platforms - Implications for the U.S.-Taiwan Relationship. United States Department of State, Washington DC September 2nd, 2015.

Invited Lecture: Targeted Cancer Immunotherapy. Long Island Jewish Medical Center/Cold Spring Harbor Cancer Center, Queens, NY 2015. Massachusetts General Hospital: New Developments in Cancer Immunology, Boston, MA 2015 Invited Presentation: “Shifting Sands: Organ-Sparing Surgery: Prostate”. Société Internationale d’Urologie. Glasgow, Scotland. October 13, 2014. Invited Presentation: “Update on Management of Advance Prostate Cancer”. International Society of Men’s Health and Academy of Family Physicians of Malaysia Joint Annual Meeting. Kuching, Malaysia. May 23, 2014. Invited Presentation: “AUA Office of Research Report”. American Urological Association Board of Directors Fall Meeting. Orlando, FL. May 15, 2014. Invited Presentation: “Is There a Role for a Dedicated Research Year in Urologic Residency Training?” Society for Urology Chairpersons and Program Directors Annual Meeting. Orlando, FL. May 16, 2014. Invited Presentation: “Suppressing Immune Suppression”. American Association of Genitourinary Surgeons Annual Meeting. Amelia Island, FL. April 24, 2014. Invited Moderator: “Discovery and Innovation in Urology”. Southeastern Section of the American Urological Association Annual Meeting. Hollywood, FL. March 20, 2014. Poster Presentation: “Clinical Practice Guidelines for Prostate Cancer: a Critical Appraisal”. Southeastern Section of the American Urological Association Annual Meeting. Hollywood, FL. March 20, 2014. Invited Presentation: “Update on Targeted Therapies for Advanced Renal Cell Carcinoma”. UF Department of Urology CME Conference. Orlando, FL. February 22, 2014. Invited Presentation: “AUA Office of Research Report”. American Urological Association Board of Directors Fall Meeting. Linthicum, MD. October 18, 2013.

Invited Presentation: “Florida Prostate Cancer Advisory Council”. Florida Urological Society Annual Meeting. Tampa, FL. August 30, 2013. Grand Rounds Presentation: “Integration of Community Urologists into an Academic Network”. Carolina’s HealthCare Department of Urology. Charlotte, NC. August 2, 2013. Invited Presentation: “Prostate Cancer: A Serious Health Threat Affecting Floridian Men and Our Health Care System”. The People’s Conference. Gainesville, FL. June 14, 2013. Invited Presentation: “State of Florida Prostate Cancer Advisory Council”. Florida Bio Medical Research Program Advisory Council. Orlando, FL. June 10, 2013. Invited Presentation: “Rising Stars Report”. Plenary Session of the American Urological Association Annual Meeting. San Diego, CA. May 8, 2013. Invited Presentation: “Highlights on Oncology Research: Excerpts from the 2013 Urology Oncology Symposium Pathways to Therapy”. Plenary Session of the American Urological Association Annual Meeting. San Diego, CA. May 5, 2013. Invited Presentation: “Urology Research: Laboratory vs. Outcomes”. Society of University Urologists Annual Meeting. San Diego, CA. May 3, 2013. Invited Presentation: “A Primer on Team Science and its Implications on Urology Research”. American Urological Association Annual Meeting. San Diego, CA. May 3, 2013. Invited Presentation: “Research Progress in a Challenging Environment”. American Urological Association Board of Directors Meeting. San Diego, CA. May 2, 2013. Invited Presentation: “Activities of the State of Florida Prostate Cancer Advisory Council”. System of Cancer Care Symposium. Tallahassee, FL. April 19, 2013. Invited Presentation: “Stem Cell-Derived Dendritic Cells: Towards a Universal Tumor Vaccine”. American Association of Genitourinary Surgeons. New Orleans, LA. April 4, 2013. Podium Presentation Moderator: “Prostate Cancer Podium”. Southeastern Section of the American Urological Association. Williamsburg, VA. March 14, 2013. Invited Presentation: “Active Surveillance for Prostate Cancer Economic Implications”. University of Florida Department of Urology CME Seminar Series. Orlando, FL. February, 2013. Invited Presentation: “State of the Office of Research”. American Urological Association Board of Directors Fall Meeting. Linthicum, MD. October 18, 2012. Invited Presentation: “AUA Office of Research: New Structure”. Society of Urologic Oncology Board of Directors Annual Meeting. Atlanta, GA. May 18, 2012. Invited Presentation: “Approaches to Research Funding”. Society of Pediatric Urology Annual Meeting. Atlanta, GA. May 19, 2012. Invited Presentation: “Prostate Cancer Microenvironment and Vaccines”. Florida Prostate Cancer Symposium “Molecular Mechanisms Underlying Prostate Cancer Progression. Orlando, FL. May 5, 2012. Invited Presentation: “The PSA Screening Dilemma – To Test or Not To Test”. The 5th Annual W. Bradford Ingalls Memorial Prostate Health and Cancer Seminar. Jupiter, FL. March 3, 2012. Invited Presentation: “Prostate Cancer: Current Screening Policy Debates and Recommendations”. North Central Florida Cancer Control Collaborative. Gainesville, FL. February 29, 2012.

Invited Presentation: “Organization of Prostate Cancer Care in Florida”. University of Florida Department of Urology CME Seminar Series. Orlando, FL February 18, 2012. Invited Presentation: “Welcome”. 1st Annual Robotic Assisted Microsurgical and Endoscopy Society Robotic Microsurgery Symposium. Orlando, FL. November 5, 2011. Invited Presentation: “Considerations for Designing Investigator Initiated Clinical Trials”. BioFlorida Fourteenth Annual Conference. Tampa, FL. October 25, 2011. Invited Presentation: “State of the Office of Research”. American Urological Association Board of Directors Fall Meeting. Linthicum, MD. October 14, 2011. Invited Lecture: “State of Prostate Cancer Awareness & Information in Florida”. University of Florida Prostate Disease Center State of Florida Prostate Advisory Council. Orlando, FL. September 10, 2011. Invited Lecture: “Targeted Therapeutics for Urologic Malignancies-Bench to Bedside”. Florida Urological Society Annual Meeting. Coconut Point, FL. September 3, 2011. Invited Lecture: “State of Florida Prostate Cancer Task Force”. Florida Urological Society. Coconut Point, FL. September 2, 2011. Invited Lecture: “Advances in the Design and Clinical Implementations of Cancer Vaccines”. Barbara Ann Karmanos Cancer Institute Grand Rounds. Detroit, MI. June 30, 2011. Plenary Session: “News from Rising Stars: a review of the last 30 years of the AUA’s Research Scholars Program”. American Urological Association Annual Meeting. Washington, DC. May 15, 2011. Podium Presentation Moderator: “Prostate Cancer: epidemiology & natural history”. American Urological Association. Washington, DC. May 15, 2011. Invited Lecture: “Genetically Engineered Dendritic Cells for Immunologic Therapies of Urologic Cancers”. Fred Hutchinson Cancer Research Center SPORE/PPCR Seminar Series. Seattle, WA, April 21, 2011. Invited Lecture: “Male Sexuality and Treatment of Erectile Dysfunction”. University of Florida Department of Psychiatry Grand Rounds, Gainesville, FL, April 8, 2011. Invited Lecture: “What the AUA Means to Me”. Southeastern Section of the American Urological Association Annual Meeting. New Orleans, LA, March 20, 2011. Poster Presentation: “Residents for Quality Improvement in Urology (RESQU): Three year experience with a resident-centered quality improvement initiative”. Southeastern Section of the American Urological Association Annual Meeting. New Orleans, LA, March 18, 2011. Invited Lecture: “Cancer Vaccines in Urology”. University of Florida Department of Urology Grand Rounds, Gainesville, FL, March 9, 2011. Webinar Presentation: “Decision Making Tools for Prostate Cancer Screening”. Florida Department of Health, Tallahassee, FL, September 28, 2010. Invited Lecture: “AUAF Research Council: Ensure Enduring Support for Urology Research and Development”. Florida Urological Society. Orlando, FL, September 4, 2010. Podium Presentation: “Infertility: Physiology, Pathophysiology, Basic Research”. American Urological Association Annual Meeting. San Francisco, CA. June 2, 2010. Poster Session Moderator: “Prostate cancer: Localized VIII”. American Urological Association Annual Meeting. San Francisco, CA. June 2, 2010.

Plenary Session: “60 Years of Progress at the NIDDK: What the Future Holds”. American Urological Association Annual Meeting. San Francisco, CA. May 31, 2010. Invited Lecture: “Development of a Universal Cancer Vaccine Platform”. H. Lee Moffitt Cancer Center Grand Rounds. Tampa, FL, May 21, 2010 Invited Lecture: “Prostate Cancer: Diagnostic Evaluation and Treatment”. 3rd Annual W.B. Ingalls Memorial Prostate Health and Cancer Seminar. Jupiter, FL, March 20, 2010. Invited Lecture: The Montague Boyd Essay Contest “Reporting quality and information consistency of randomized controlled trials presented at the American Urological Association annual meetings”. Southeastern Section of the American Urological Association. Miami, FL, March 12, 2010. Podium Presentation: “Intra-operative Doppler phase shift to localize the present of sperm during testis biopsy in azoospermic men”. Southeastern Section of the American Urological Association, Miami, FL, March 11, 2010. Podium Presentation: “Robotic-assisted microsurgery: The initial 102 case experience”. Southeastern Section of the American Urological Association, Miami, FL, March 11, 2010. Podium Presentation: “Evaluating the evidence: Quality of reporting of studies on robotic-assisted laparoscopic prostatectomy”. Southeastern Section of the American Urological Association, Miami, FL, March 11, 2010. Invited Lecture: The Ballenger Lecture “Cancer Vaccines: Advances in the Design & Clinical Implementation of Cancer Vaccines”. Southeastern Section of the American Urological Association, Miami, FL, March 12, 2010. Poster Presentation: “Anatomic basis of Denervation of the spermatic cord for chronic Orchialgia”. Southeastern Section of the American Urological Association, Miami, FL, March 13, 2010. Invited Lecture: “Cancer Vaccines: Harnessing the Immune Response Against Prostate and Renal Cell Carcinoma”. University of Florida College of Pharmacy Department of Pharmacotherapy and Translational Research Seminar Series, Gainesville, FL, January 8, 2010. Invited Lecture: “Targeted Therapies in Prostate Cancer: From Small Molecule Inhibitors to Cancer Vaccines”. 61st Congress of the German Urological Society, Dresden, Germany, September 18, 2009. Invited Lecture: “Prostate Cancer in Florida”. Florida Urological Society, Naples, FL, September 6, 2009. Invited Lecture: “Design & Application of Biological Therapies Against Urologic Malignancies”, Global Gators Pharmacology Conference, Stresa, Italy, June 13, 2009. Podium Presentation: “Infertility: Evaluation”, AUA Annual Meeting, Chicago, IL, April 29, 2009. Poster Presentation: “Technology & Instruments: Robotics/Laparoscopy”, AUA Annual Meeting, Chicago, IL, April 28, 2009. Poster Presentation: “General & Epidemiological Trends & Socioeconomics: Evidence-based Medicine and Outcome Analysis”, AUA Annual Meeting, Chicago, IL, April 25, 2009. Poster Presentation: “The reporting quality of randomized controlled trials presented in abstract form at the American Urological Association Annual Meeting”, AUA Annual Meeting, Chicago, IL, April 25, 2009. Poster Presentation: “An Observational Study of the Information Consistency of Urological Abstracts and Subsequent Full-text Publications”, AUA Annual Meeting, Chicago, IL, April 25, 2009.

Poster Presentation: “Robotic Assisted Microsurgical Varicocelectomy”, AUA Annual Meeting, Chicago, IL, April 25, 2009. Poster Presentation: “3D Ultrasound Image Guided Fixed Platform Transrectal Prostate Biopsy”, AUA Annual Meeting, Chicago, IL, April 25, 2009. Poster Presentation: “Robotic Assisted Microsurgical Denervation of the Spermatic Cord”, AUA Annual Meeting, Chicago, IL, April 25, 2009. Presentation: “Residents for Quality Improvement in Urology (RESQU): Integrating Quality Improvement into a Urologic Residency Program Curriculum”, Society of Urology Chairpersons & Program Directors, Chicago, IL, April 24, 2009. Invited Lecture: “Eliminating Regulatory Factors and Augmenting the Vaccine-induced T-cell Response”, University of Florida Department of Medicine GI/Liver Research Conference, Gainesville, FL, March 5, 2009. Invited Lecture: “Active immunotherapy against cancer: new developments”, College of Medicine Department of Medicine Grand Rounds, Gainesville, FL, May 29, 2008. Poster Presentation: “Evidence-Based Medicine Training in Residency: a Survey of Urology Program Directors”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Poster Presentation: “Clinical Practice Guidelines for Prostate Cancer: a Critical Appraisal of Methodological Quality”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Poster Presentation: “Interobserver Agreement in the Application of Levels of Evidence Ratings to the Urological Literature”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Poster Presentation: “Perceptions and Competence in Evidence-Based Medicine: Results of the 2006 Survey of AUA Members”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Presentation: “Robotic and Laparoscopic Partial Nephrectomy without Vascular Clamping and Renal Ischemia”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Presentation: “Human Robotic Bilateral Vasoepididymostomy and Vasovasostomy Procedures”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Presentation: “Robotic Renal Surgery – Diamond 4-ARM Port Configuration and Body Mass Index-Based Neural Network Port Adjustments”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Presentation: “Handheld Intra-Operative Doppler Flow to Localize the Presence of Sperm During Testis Biopsy in Azoospermic Men”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Video Session: “Video Demonstration of Robotic Testicular Sperm Extraction: Critical Evaluation Compared to Open Tese and Percutaneous Needle Lavage Techniques in Canine model and the First Human Cases”, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Video Session: “Video Demonstration of Laparoscopic Doppler Identification of Crossing Vessel During Robotic or Laparoscopic Dismembered Pyeloplasty – a Possible Tool to Decrease Operative Time?, AUA Annual Meeting, Orlando, FL, May 17 - 20, 2008. Moderated Poster: “Prostate Cancer: Localized (IV): Evaluating the Evidence: Quality of Reporting of Studies on Robotic-Assisted Laparoscopic Prostatectomy”, AUA Annual Meeting, Orlando, FL, May 17 – 20, 2008. Invited Lecture: “Translational Research: Lessons Learned from Cancer Immunotherapy Applications”, 2007 College of Medicine Research Day, Gainesville, FL, April 23, 2008.

Invited Lecture: “Translational Research in Urologic Oncology”, FUS Annual Meeting, Miami Beach, FL, August 30 – September 2, 2007. Invited Lecture: “Contemporary Treatment of Advanced/Metastatic RCC”, FUS Annual Meeting, Miami Beach, FL, August 30 – September 2, 2007. Poster Presentation: “Prostate Cancer: Basic Research (V) Generation of Semi-allogeneic Dendritic Cells Derived from Human Embryonic Stem cells for Urologic Cancer Immunotherapy”, AUA Annual Meeting, Anaheim, CA, May 18-23, 2007. Poster Presentation: “Levels of Evidence in the Urology Literature”, 2007 AUA Annual Meeting, Anaheim, CA, May 18-23, 2007. Poster Session: “Barriers to the Practice of Evidence Based Urology in the United States”, 2007 AUA Annual Meeting, Anaheim, CA, May 18-23, 2007. Presentation: “History of Urology: A tribute to the Life and Accomplishments of Birdwell Finlayson”, 2007 AUA Annual Meeting, Anaheim, CA, May 18-23, 2007. Invited Lecture: “Translational Research in Urologic Oncology”, CureVac – GmbH, Boston, MA, May 8- 9, 2007. Visiting Professor: “Update on Renal Cell Carcinoma”, Deane Prostate Health & Research Center, Mt. Sinai School of Medicine, New York, NY, May 1-3, 2007. Abstract: “Tumor Mediated Immunosuppression Through Myeloid Suppressive Cells”, 71st SESAUA Annual Meeting, Orlando, FL, March 8-11, 2007. Abstract: “Emerging Strategies for Metastatic Prostate Cancer”, ASCO – The Prostate Cancer Symposium, Orlando, FL, February 22-24, 2007. Invited Lecture: “Immunosuppressive Networks in Renal Cell Carcinoma”, Molecular Targets in Cancer Immunotherapy, Clearwater, FL, January 25-28, 2007. Invited Lecture: “Clinical Trial Designs for Prostate Cancers”, Merck/EMD Pharmaceuticals Advisory Meeting, Miami, FL, January 19-28, 2007. Invited Lecture: “Cancer Vaccines”, Oak Hammock, Gainesville, FL, December 7, 2006. Invited Lecture: “Combinatorial Approaches in Cancer Immunotherapy”, Cancer Vaccine Consortium 8th Annual Colloquium, Washington, DC, November 9-10, 2006. Invited Lecture: “Translational Strategies to Enhance Dendritic Cell Mediated Antitumor Immunity”, 2006 ASCO Annual Meeting, Atlanta, GA, June 2-6, 2006. Poster presentation: “Factors Associated with the Full Publication of Studies Presented in Abstract Form at the Annual Meeting of the AUA” Poster presentation: Evaluating the Evidence: Randomized Controlled Trial Reporting in the Urologic Literature; 2006 AUA Annual Meeting, Atlanta, GA, May 20-25, 2006 Poster presentation: Identification of angiogenesis-associated gene products for renal cell carcinoma immunotherapy; 2006 AUA Annual Meeting, Atlanta, GA, May 20-25, 2006 Poster presentation: Enhancement of vaccine-mediated antitumor immunity in renal cell carcinoma (RCC) patients after in vivo depletion of regulatory T cells. Results from a phase-I clinical trial; 2006 AUA Annual Meeting, Atlanta, GA, May 20-25, 2006

Poster presentation: Impact of the Nerve-Sparing Technique on Patients Self-Assessed Functional Outcomes in Radical Perineal Prostatectomy. 2006 AUA Annual Meeting, Atlanta, GA, May 20-25, 2006. Invited Lecture: “Importance of Regulatory T cells in Modulating Immune Responses,” Society for Investigative Dermatology, Vision 2008 Conference, Philadelphia, PA, May 2-3, 2006. Invited Lecture: “Depletion of Regulatory T cells Using the Interleukin-2 Diphtheria Toxin Fusion Protein Denileukin Difitox, ONTAK®,” Innovations and Challenges in Renal Cancer Conference, Cambridge, MA, April 27-29, 2006. Oral Presentation: “In situ Activation of Dendritic Cells (DC) with Imiquimod for Cancer Immunotherapy”; Poster presentations: “TIE-2 is a promising anti-angiogenic target for immunotherapy of renal cell cancer,” “Immature myeloid cell (ImC) – mediated immunosuppression in advanced renal cell cancer (RCC),” AACR Annual Meeting, Washington, DC, April 1-5, 2006. Invited Lecture: “Cancer Vaccines in Urologic Malignancies-Inching toward the Finish Line”, and “Clinical application of Stem Cells in Urologic Disease – Promise and Controversies”, Duke Urologic Association Annual Meeting, Orlando, FL., March 29-30, 2006. Invited Lecture: “Clinical translation of novel concepts to enhance vaccine-mediated anti-tumor immunity”, John’s Hopkins, Baltimore, MD., January 12-13, 2006. Invited Lecture: “Translational Strategies to Enhance Dendritic Cell Mediated Antitumor Immunity”, Perspectives in Melanoma IX Conference, Tampa, FL, November 17-18, 2005. Invited Co-Chair, Plenary Session: “Turning Immunization into Tumor Regression: Obstacles and Strategies”, International Society for Biological Therapy of Cancer, Alexandria, VA, November 13-14, 2005. Invited Lecture: “Translational Research in Urology”, 21st Annual Meeting, Urological Research Society, Boston, MA, November 10-12, 2005. Invited Lecture: “Dendritic Cell Vaccines: Are they Clinically Relevant?”, 4th International Kidney Cancer Symposium, Chicago, IL, October 21-22, 2005 Invited Lecture: “Combinatorial Cancer Immunotherapy – Enhancing Anti-Tumor Immunity and Abrogating Suppressive Elements”, The Cleveland Clinic, Cleveland, OH, October 11-12, 2005. Invited Lecture and Grand Rounds: “Clinical Translation of Novel Concepts to Enhance Vaccine-Mediated Antitumor Immunity”, “Translational Research – lessons learned from cancer immunotherapy development”, Baylor College of Medicine, Houston, TX, August 15-17, 2005. Invited Lecture: “Translational Research in Academic Medical Centers – Lessons from Development of Cancer Immunotherapy”, University of Wisconsin, Madison, WI, July 19-21, 2005. Invited Lecture: “Dendritic Cell Vaccines”, 2nd International Congress on Kidney & Bladder Cancer, Orlando, FL, July 15-16, 2005. Invited Lecture: “Novel Approaches to Enhance Vaccine-Mediated Antitumor Immunity”, 2nd International Tegernsee Immunotherapy Conference, Tegernsee, Germany, June 29-Juy 3, 2005. Poster Presentation: “Safety and Efficacy of Human Telomerase Reverse Transcriptase mRNA Transfected Dendritic Cells in Patients with Metastatic Prostate Cancer: results of a phase I Clinical Trial”, AUA, San Antonio, TX, May 20-24, 2005. Poster Presentation: “Targeted Immunotherapy against Genitourinary Malignancies using RNA- Transfected DC Vaccines”, AUA, San Antonio, TX, May 20-24, 2005.

Poster Session: “Reversal of immature myeloid cell-mediated immunosuppression”, ASCO, Orlando, FL, May 13-17, 2005. Poster Session: “Cellular Mechanisms of Regulation of Tumor Immunity” AACR, Anaheim, CA, April 17- 20, 2005. Poster Session: “Dendritic Cell-based Immunotherapy”, AACR, Anaheim, CA, April 17-20, 2005. Invited Lecture: Vaccine Trials in Prostate Cancer. Duke Prostate Center (DPC) Symposium, Durham, NC, April 9, 2005. Invited Lecture: Disruption of Regulatory Pathways to Enhance the Efficacy of Cancer Vaccines. Basic Aspects of Tumor Immunology II, Keystone, CO, March 19-24, 2005. Invited Lecture: “Contemporary Results of Radical Cystectomy and Pelvic Lymphadenectomy in Muscle Invasive Bladder Cancer”. Duke Urologic Assembly, Curacao, Netherlands Antilles March 15-20, 2005. Invited Lecture: “New Approaches in the Treatment of Metastatic Renal Cell Carcinoma: Emerging Concepts. Duke Urologic Assembly, Curacao, Netherlands Antilles, March 15-20, 2005. Invited Lecture: “Translational Research in Academic Medical Centers”. Surgical Grand Rounds, Duke University Medical Center, Durham, NC, March 2, 2005. Invited Lecture: “Strategies to Enhance Vaccine-Mediated Antitumor Immunity”. Partners Cancer Care, Massachusetts General Hospital/Dana Farber Institute, Boston, MA, December 14, 2004. Invited Lecture: “Transfected Dendritic Cells”. 3rd International Kidney Cancer Symposium, Chicago, IL, November 12, 2004. Invited Lecture: “Strategies to enhance DC-mediated antitumor immunity”. International Society for the Biological Therapy of Cancer (iSBTc), 19th Annual Meeting, San Francisco, CA, November 4, 2004. Invited Lecture: “Strategies to Enhance Vaccine-Mediated Antitumor Immunity”. Phacilitate Vaccine Fall Forum 2004, Cambridge, MA, November 3-4, 2004. Poster Presentation: Enhancement of Antitumor Immunity following in-vivo depletion of CD4+CD25+ Regulatory T Cells. 8th Int’l DC Symposium, Brugge, Belgium, October 17-21, 2004. Poster Presentation: Enhanced Antigen Presenting Function of Antigen-Loaded Dendritic Cells following Co-transfection with OX40 Ligand mRNA”. 8th Int’l DC Symposium, Brugge, Belgium, October 17-21, 2004. Invited Lecture: Translational Research-How to achieve Societal Benefit through Academic Discovery; Australian Prostate Cancer Collaboration (Queensland Institute of Medical Research and the Mater Medical Research Center), Queensland, Australia, September 10-19, 2004. Invited Lecture: RNA transfected dendritic cells-implications for immunotherapy for Urologic malignancies. Australian Prostate Cancer Collaboration (Queensland Institute of Medical Research and the Mater Medical Research Center), Queensland, Australia, September 10-19, 2004. Invited Lecture: “Pathways to enhance vaccine-mediated antitumor immunity”. International Workshop on Cancer Vaccines, Siena, Italy, June 13-15, 2004. Invited Lecture: “Immunotherapy of Urologic Cancers – Are we there yet?” United States Department of Defense Center for Prostate Disease Research, Rockville, MD, June 12-13, 2004. Oral Presentation: “Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: Results

from a Phase I Clinical Trial. American Society of Clinical Oncology Annual Meeting, New Orleans, LA, June 3-4, 2004. Oral Presentation: Enhancement of antitumor immunity following depletion of CD4+CD25+ regulatory T cells.” American Society of Clinical Oncology Annual Meeting, New Orleans, LA, June 3-4, 2004. Invited Lecture: “Polyvalent Vaccine Strategy in the Treatment of Metastatic Renal Cell Carcinoma.” American Association of Pharmaceutical Scientists National Biotechnology Conference, Boston, MA, May 16-19, 2004. Poster Presentation: “Vaccination of Metastatic Prostate Cancer Patients Using Mature Dendritic Cells Transfected with mRNA Encoding hTERT or an MHC Class II Targeted hTERT/LAMP Fusion Protein: Results From a Phase I Clinical Trial.” American Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27-31, 2004. Poster Presentation: “Enhancement of Antitumor Immunity Following Depletion of CD4+CD25+ Regulatory T Cells.” American Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27-31, 2004. Poster Presentation: “Enhanced Antigen Presenting Function of Antigen-Loaded Dendritic Cells Following Co-transfection with OX40 Ligand mRNA.” American Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27-31, 2004. Invited Lecture: “Translational Research Strategies.” University of Michigan, Ann Arbor, MI, March 24-26, 2004. Invited Lecture: “Therapeutic Strategies for the Management of Metastatic Renal Cell Carcinoma.” Duke Urologic Assembly, St. Kitts, British West Indies, March 9-13, 2004. Invited Lecture: “The Role of Chemotherapy, Radiation Therapy and Surgery for Transitional Cell Carcinoma.” Duke Urologic Assembly, St. Kitts, British West Indies, March 9-13, 2004. Invited Lecture: “Clinically Applicable Strategies to Enhance Vaccine-Mediated Antitumor Immunity.” University of Michigan, Ann Arbor, MI, January 8-9, 2004. Invited Lecture: “Strategies to Augment the Efficacy of Dendritic Cell-Based Vaccines.” The American Society of Hematology Annual Meeting, San Diego, CA, December 6-9, 2003. Lecture: “Bladder Preservation in Muscle-Invasive Bladder Cancer: An Attainable Goal?” Duke Tuesday – Duke University Medical Center, Durham, NC, December 2, 2003. Oral Presentation: “Radical Perineal vs. Radical Retropubic Prostatectomy: Competing or Complementary Procedures?” American Urological Association - 101st Annual Meeting (New York Section), Athens, Greece, October 10-18, 2003. Invited Lecture: “Translational Research Strategies in an Academic Setting.” University of Minnesota Seminar, Minneapolis, MN, June 29-July 1, 2003. Invited Lecture: “Mature DC Transfected with RNA Encoding Human Telomerase Reverse Transcriptase (hTERT).” 4th International Expert Dendritic Cell Conference, Amsterdam, June 11-17, 2003. Invited Lecture: “RNA Transfected Dendritic Cells Preclinical and Clinical Trials.” MD Anderson Cancer Center, Houston, TX, May 12-13, 2003. Invited Lecture: “Regulatory Issues in Cell Therapy.” MD Anderson Cancer Center, Houston, TX, May 12- 13, 2003.

Oral Presentation: “Dendritic Cell Immunology.” American Urology Association – Kidney Cancer Workshop (ACOSOG), University of Chicago, Chicago, IL, April 25, 2003. Invited Lecture: “RNA Transfected Dendritic Cells-Implications for Cancer Immunotherapy.” East Carolina University Seminar, Greenville, NC, April 15, 2003. Oral Presentation: “Vaccination of Patients with Hormone-Refractory Prostate Cancer Using Telomerase RNA Transfected DC: Results From a Phase I Clinical Trial.” American Association of Cancer Research, Toronto, Canada, April 5-9, 2003. Oral Presentation: “Enhancement of T-cell Responses against Renal Cell Carcinoma by Elimination of Regulatory T Cells.” American Association of Cancer Research, Toronto, Canada, April 5-9, 2003. Lecture: “Update on Novel Strategies in the Management of Metastatic Renal Cell Carcinoma.” Duke Urologic Assembly, Puerto Vallarta, Mexico, March 11-15, 2003. Lecture: “Radical Perineal vs. Radical Retropubic Prostatectomy: Competitive or Complementary Strategies?” Duke Urologic Assembly, Puerto Vallarta, Mexico, March 11-15, 2003. Oral Presentation: “Vaccination of Patients with Hormone-Refractory Prostate Cancer Using Telomerase RNA Transfected DC: Results from a Phase I Clinical Trial.” Keystone Symposia, Keystone, CO, March 3- 7, 2003. Oral Presentation: “Dendritic Cell Therapy for Genitourinary Malignancies.” 3rd Annual Urologic Oncology Meeting, Bethesda, MD, December 13-14, 2002. Poster Presentation: “Immunological and Clinical Responses in Patients with Metastatic Renal Cell Carcinoma to Vaccination with Tumor RNA Transfected Dendritic Cells.” American Society of Hematology 44th Annual Meeting and Exposition, Philadelphia, PA, December 6-10, 2002. Invited Lecture: “Renal Cell Carcinoma: Predicting Prognosis.” Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology: State of the Art, New York University Post- Graduate Medical School Course, New York, NY, December 5-7, 2002. Invited Lecture: “Emerging Immune-Based Strategies for Advanced Renal Cell Carcinoma.” Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology: State of the Art, New York University Post-Graduate Medical School Course, New York, NY, December 5-7, 2002. Invited Lecture: “Novel Tumor Vaccine Approaches for Malignant Melanoma.” Melanoma Cooperative Group, Duke University Medical Center, Durham, NC, October 15, 2002. Invited Lecture: “Dendritic Cell Vaccine Transfected with RNA Encoded Antigens Experiences from Clinical Trials.” 2nd International Conference on Prostate Cancer Research, Iowa City, IA, October 12-15, 2002. Oral Presentation: “Induction of Tumor-Specific T Cell Responses in Patients with Metastatic Renal Cell Carcinoma Following Vaccination with Dendritic Cells Transfected with Tumor RNA.” 7th International Symposium on Dendritic Cells, Bamberg, Germany, September 19-24, 2002. Oral Presentation: “Enhancement of T Cell Responses Against Renal Cell Carcinoma by Elimination of Regulatory T Cells.” 7th International Symposium on Dendritic Cells, Bamberg, Germany, September 19- 24, 2002. Oral Presentation: “Immune Based Approaches for Genitourinary Malignancies.” Urology Research Society Meeting, York, England, September 4-7, 2002. Invited Lecture: “Emerging Therapies for Urologic Cancers.” 4th International Dresden Symposium, Dresden, Germany, June 21-23, 2002.

Oral Presentation: “RNA Transfected DC Vaccines – Preclinical and Clinical Results.” Concepts in Immunotherapy of Cancer Conference, Mainz, Germany, June 13-14, 2002. Oral Presentation: “Telomerase RNA Loaded Dendritic Cell Vaccines.” American Urologic Association Annual Meeting, Orlando, FL, May 25-30, 2002. Poster Presentation: “Phase I Clinical Trial Using Dendritic Cells Transfected with PSA RNA for Immunotherapy of Prostate Cancer Patients.” American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, April 6-10, 2002. Poster Presentation: “Stimulation of Human Telomerase (hTERT) Specific CD8+ and CD4+ T Cell Responses Using Autologous Dendritic Cells Transfected with RNA Encoding TERT Transcripts Containing a Lysosomal Targeting Signal (LAMP).” American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, April 6-10, 2002. Invited Lecture: “Telomerase Transfected RNA Dendritic Cell Vaccines.” Morris Center for Urologic Research Meeting, Durham, NC, April 19, 2002. Lecture: “Dendritic Cell Vaccine Therapy.” Duke Urologic Assembly, Aruba, March 12-17, 2002. Lecture: “Outcomes in Renal Cell Carcinoma.” Duke Urologic Assembly, Aruba, March 12-17, 2002. Invited Lecture: “RNA Transfected DC Vaccines.” ABMT Grand Rounds, Duke University Medical Center, Durham, NC, December 18, 2001. Poster Presentation: “Stimulation of Human Telomerase (hTERT) Specific CD8+ and CD4+ T Cell Responses Using Autologous Dendritic Cells Transfected with RNA Encoding TERT Transcripts Containing a Lysosomal Targeting Signal (LAMP).” American Society of Hematology Annual Meeting, Orlando, FL, December 7-12, 2001. Invited Lecture: “RNA Transfected DC Vaccines and Preclinical Results.” Memorial Sloan-Kettering Cancer Center, New York, NY, September 24-25, 2001. Poster Presentation: “Stimulation of Cytotoxic T Cell Response in Patients with Metastatic Prostate Cancer Using Autologous Dendritic Cells Transfected with RNA Encoding Prostate Specific Antigen (PSA) – Results of Phase I Clinical Trial.” CaPCURE 8th Annual Scientific Retreat, Lake Tahoe, NV, September 6- 9, 2001. Invited Lecture: “Immunotherapy.” AUA Research Conference: Molecular Approaches to Therapy in Urologic Diseases, Houston, TX, August 10-12, 2001. Poster Presentation: “Dendritic Cell Based Vaccines for Renal Cell Carcinoma Using Tumor Antigen Encoded by Total Tumor RNA.” American Urologic Association, Anaheim, CA, June 2-7, 2001. Invited Lecture: “RNA Transfected DC Vaccines – Preclinical and Clinical Results.” Cancer Vaccines Conference, San Diego, CA, May 21-22, 2001. Oral Presentation: “Immunotherapy of Prostate Cancer using Dendritic Cells Transfected with PSA RNA: Results of a Phase I Trial.” American Society of Clinical Oncology 37th Annual Meeting, San Francisco, CA, May 12-15, 2001. Oral Presentation: “Dendritic Cell Vaccines Transfected with RNA Encoded Antigens Experiences from Clinical Trials.” American Association of Genitourinary Surgeons Conference, San Francisco, CA, April 18-21, 2001. Oral Presentation: “Tumor RNA Transfected Dendritic Cells: A Phase I Study Results.” Dendritic Cells: Keystone Symposia, Taos, NM, March 12-18, 2001.

Oral Presentation: “Immunotherapy of Prostate Cancer Using Dendritic Cells Transfected with PSA RNA: Results of a Phase I Trial.” Urologic Investigators’ Forum, Marco Island, FL, March 2-4, 2001. Invited Lecture: “RNA Transfected Dendritic Cells Vaccine – Preclinical and Clinical Results.” H. Lee Moffitt Cancer Center, Tampa, FL, November 28-29, 2000. Poster Presentation: “Immunotherapy of Prostate Cancer Using Dendritic Cells Transfected with RNA Encoded Tumor Antigens.” Society for Basic Urologic Research Fall Symposium, Fort Myers, FL, November 9-12, 2000. Poster Presentation: “Immunotherapy of Prostate Cancer Using Dendritic Cells Transfected with RNA Encoded Tumor Antigens.” CRI International Symposium, Cancer Vaccines 2000, New York, NY, October 2-4, 2000. Poster Presentation: “Immunotherapy of Metastatic Prostate Cancer Using Dendritic Cells Transfected with mRNA Encoding Prostate Specific Antigen (PSA).” CaPCURE 7th Annual Scientific Retreat, Lake Tahoe, NV, September 21-24, 2000. Poster Presentation: “Dendritic Cells Based Vaccines for Renal Cell Carcinoma Using Tumor Antigen Encoded in Total Tumor RNA.” 1st International Scientific Meeting, Society for Biological Therapy, Berlin, Germany, September 13-16, 2000. Poster Presentation: “In Vitro Induction of CTL Using Dendritic Cells Transfected with Amplified Prostate Tumor RNA Results in a Prostate Cancer Specific Response.” 6th Annual International Symposium on Dendritic Cells, Queensland, Australia, May 26-June 1, 2000. Oral Presentation: “Human Dendritic Cells Transfected with RNA Encoding Specific Antigen (PSA) Can Stimulate Potent Prostate Specific CTI Responses In Vitro.” American Urologic Association, Atlanta, GA, April 29-May 4, 2000. Invited Lecture: “Immunotherapy of Prostate Cancer Using Tumor RNA Transfected Dendritic Cells.” Advances in Human Breast and Prostate Cancer: Keystone Symposia, Lake Tahoe, NV, March 22-24, 2000. Oral Presentation: “RNA Delivery in Prostate and Renal Cancer.” Dendritic Cell Expert Meeting, Zurich, Switzerland, February 9-14, 2000. Oral Presentation: “Dendritic Cells Based Vaccines for Renal Cell Carcinoma using Tumor Antigen Encoded by Total Tumor RNA.” Immunotherapy of Cancer: Keystone Symposia, Santa Fe, NM, January 21-27, 2000. Oral Presentation: “Induction of Polyclonal Prostate Cancer Specific CTL In Vitro Using Dendritic Cells Transfected with Amplified Prostate Tumor RNA.” Immunotherapy of Cancer: Keystone Symposia, Santa Fe, NM, January 21-27, 2000.